Contact

Actineer, the joint venture between ITM and CNL, is addressing the growing and urgent global demand for Actinium-225—a rare medical radioisotope that enables the development of innovative therapies for hard-to-treat tumors. By ensuring a stable, scalable supply of this critical resource, Actineer helps to advance both clinical trials and the development of potential life-saving treatments for cancer patients worldwide.

Our joint venture Actineer has been launched with the overall goal to ensure access to Ac-225 as a next generation radioisotope through an innovative technology.
With the foundation of Actineer we have committed us to establish a reliable, long term and substantial production of Ac-225 in high quality standards.
This Canada based company will facilitate ground breaking research activities leading to novel cancer treatments urgently needed by many patients worldwide.

It is our role to drive nuclear innovation in Canada, to bring private and public expertise together to spark these new initiatives that will ultimately benefit the health of Canadians and bring new jobs to Canada. We are building on decades of Canada’s world-leading isotope innovation, and have found the key to success is collaboration, partnership, and strong leadership. We are pleased to support the joint venture between CNL and ITM with shared values to bring this potentially lifesaving therapy to the world.

Actineer is poised to become one of the major global suppliers of Actinium-225. I am privileged to work with such premier institutions as CNL and ITM and am eager to leverage my expertise and work together with the Actineer team to achieve this goal and thereby support the development of innovative targeted alpha radiopharmaceuticals for the treatment of challenging cancer indications.

Targeted alpha therapies based on Actinium-225 are gaining increasing importance in addition to the well-established beta emitters such as our highly-pure non-carrier-added (n.c.a.) Lutetium-177. Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide.